Get the Stockscreener App
247.85
2.15%
5.22
Overview
News
Price History
Option Chain
Financials
Why WST Down?
Discussions
Forecast
Stock Split
Dividend History
West Pharmaceutical Services Inc stock is traded at $247.85, with a volume of 503.01K.
It is up +2.15% in the last 24 hours and up +13.23% over the past month.
West Pharmaceutical Services is based in Pennsylvania, US, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs, which include large molecule biologics, peptides such as GLP-1 receptor agonists, and small molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
See More
Previous Close:
$242.63
Open:
$244.77
24h Volume:
503.01K
Relative Volume:
0.75
Market Cap:
$17.82B
Revenue:
$2.96B
Net Income/Loss:
$487.70M
P/E Ratio:
37.10
EPS:
6.68
Net Cash Flow:
$344.00M
1W Performance:
+0.67%
1M Performance:
+13.23%
6M Performance:
+17.51%
1Y Performance:
-17.53%
1-Day Range:
$242.72
$248.41
1-Week Range:
$241.50
$250.21
52-Week Range:
$187.43
$352.33
West Pharmaceutical Services Inc Stock (WST) Company Profile
Name
West Pharmaceutical Services Inc
Sector
Industry
Phone
(610) 594-2900
Address
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
247.85 | 17.48B | 2.96B | 487.70M | 344.00M | 6.68 |
|
ISRG
Intuitive Surgical Inc
|
476.16 | 172.53B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
199.66 | 55.89B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
82.02 | 43.59B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
293.73 | 41.89B | 5.15B | 1.40B | 1.65B | 9.51 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Initiated | Barclays | Equal Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-14-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-25 | Initiated | Citigroup | Buy |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-12-24 | Upgrade | UBS | Neutral → Buy |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-11-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| Dec-14-22 | Initiated | Deutsche Bank | Hold |
| Nov-30-22 | Initiated | UBS | Neutral |
| Oct-28-22 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-14-20 | Initiated | Stephens | Equal-Weight |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-24-20 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-12-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| May-01-19 | Downgrade | Jefferies | Buy → Hold |
| Apr-23-19 | Initiated | William Blair | Outperform |
| Apr-25-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-17-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-03-17 | Initiated | Stephens | Equal-Weight |
| Sep-15-17 | Upgrade | Jefferies | Hold → Buy |
| Oct-28-16 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Sep-21-16 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Mar-22-16 | Initiated | Wells Fargo | Outperform |
| May-14-10 | Reiterated | UBS | Neutral |
| Feb-23-10 | Initiated | Jefferies & Co | Buy |
| Dec-19-08 | Initiated | UBS | Neutral |
View All
West Pharmaceutical Services Inc Stock (WST) Latest News
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day - MarketWatch
Fill Finish Manufacturing Market worth $28.14 billion by 2030 with 8.9% CAGR | MarketsandMarkets™ - PR Newswire UK
Quant Strategy Flags West Pharmaceutical Services Inc. for Entry2025 Big Picture & Community Driven Trade Alerts - beatles.ru
Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued? - 富途牛牛
Investigation announced for Long-Term Investors in shares - openPR.com
Integrated Drug Containment And Delivery Solutions Market Latest Report - InsightAce Analytic
Stock Analysis | West Pharmaceutical OutlookMixed Signals Amid Strong Fundamentals and Weak Technicals - AInvest
What is the PEG ratio of West Pharmaceutical Services Inc.2025 EndofYear Setup & Advanced Technical Signal Analysis - sundaytimes.kr
Wall Street Analysts See a 28.68% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High? - au.finance.yahoo.com
RSI Reset May Fuel Rebound in West Pharmaceutical Services Inc.July 2025 Trade Ideas & Reliable Price Action Trade Plans - beatles.ru
Two Stocks to Sell: EVgo and West Pharmaceutical Services, One Stock to Watch: Wintrust Financial - AInvest
Zacks Industry Outlook Highlights McKesson, Cardinal Health, West Pharmaceutical Services and The Cooper Companies - The Globe and Mail
CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls - TradingView
West Pharmaceutical Services, Inc. shares rise 1.24% premarket due to projected growth in Sterilization Medical Packaging Market. - AInvest
West Pharmaceutical Services (WST) Gets a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating, Raises Target Price to $310 - 富途牛牛
MCK Stock Down Despite Q1 Earnings Beat & Raised '26 EPS View - TradingView
The Best Healthcare Stocks to Buy - Morningstar
Chart Patterns Forming a Bullish Setup in West Pharmaceutical Services Inc.Low Risk Equity Screener With Results Shared - metal.it
What makes West Pharmaceutical Services Inc. stock price move sharplyTriple-digit returns - Jammu Links News
What are analysts’ price targets for West Pharmaceutical Services Inc. in the next 12 monthsBuild a portfolio that outperforms the market - Jammu Links News
How does West Pharmaceutical Services Inc. compare to its industry peersBreakout stock performance - Jammu Links News
What catalysts could drive West Pharmaceutical Services Inc. stock higher in 2025Record-breaking capital gains - Jammu Links News
When is West Pharmaceutical Services Inc. stock expected to show significant growthDynamic investment opportunities - Jammu Links News
What analysts say about West Pharmaceutical Services Inc. stockBuild wealth faster with expert stock picks - Jammu Links News
Is it the right time to buy West Pharmaceutical Services Inc. stockMaximize gains with data-driven trading alerts - Jammu Links News
Is West Pharmaceutical Services Inc. stock overvalued or undervaluedAchieve consistent profits with proven methods - Jammu Links News
How strong is West Pharmaceutical Services Inc. company’s balance sheetOver 200% growth - Jammu Links News
How volatile is West Pharmaceutical Services Inc. stock compared to the marketUnlock powerful trading tools for investors - Jammu Links News
Why is West Pharmaceutical Services Inc. stock attracting strong analyst attentionDiscover market opportunities with real-time data - Jammu Links News
West Pharmaceutical Lifts Full-Year Forecast After Strong Q2 Performance - MSN
What is the dividend policy of West Pharmaceutical Services Inc. stockTop Growth Tracker With Low Risk - Jammu Links News
How many analysts rate West Pharmaceutical Services Inc. as a “Buy”Post Market Growth Plan To Watch Now - Jammu Links News
West Pharmaceutical Services Exceeds Expectations Amidst Rising HVP DemandNews and Statistics - IndexBox
Will West Pharmaceutical Services Inc. stock recover after recent dropConservative Entry for High Return Setup Backed - metal.it
West Pharmaceutical Services: A Strategic Buy in the HVP and Biologics Boom? - AInvest
The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q2 Earnings Call - Yahoo Finance
GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises - TradingView
Intrinsic Value of West Pharmaceutical Services Inc. Stock: Is It Undervalued or OvervaluedEarly Entry Tips With Low Risk Zone Shared - metal.it
West Pharmaceutical: Q2 Earnings Suggest Recovery (NYSE:WST) - Seeking Alpha
Wall Street Analysts Think West Pharmaceutical (WST) Could Surge 25.26%: Read This Before Placing a Bet - Zacks Investment Research
Published on: 2025-07-29 21:00:13 - metal.it
Published on: 2025-07-29 18:40:03 - metal.it
How does West Pharmaceutical Services Inc. generate profit in a changing economyDaily Trading Ideas For Fast Growth - Jammu Links News
Are Bears Losing Grip on West Pharmaceutical Services Inc.AI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 09:09:27 - metal.it
Will West Pharma's Revised Guidance Drive The Stock North? - RTTNews
West Pharmaceutical Services Inc Stock (WST) Financials Data
Revenue
Net Income
Cash Flow
EPS
West Pharmaceutical Services Inc Stock (WST) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reiss-Clark Cindy | Chief Commercial Officer |
Feb 18 '25 |
Option Exercise |
211.00 |
246 |
51,940 |
5,131 |
| MacKay Kimberly Banks | SVP, GC & Corporate Secretary |
Feb 18 '25 |
Option Exercise |
211.00 |
246 |
51,940 |
1,605 |
| Favorite Annette F | Sr. VP & Chief HR Officer |
Feb 18 '25 |
Option Exercise |
211.00 |
246 |
51,940 |
6,823 |
| Winters Chad | VP, Chief Accounting Officer |
Feb 18 '25 |
Option Exercise |
211.00 |
82 |
17,313 |
1,391 |
| Witherspoon Charles | VP & Treasurer |
Feb 18 '25 |
Option Exercise |
211.00 |
66 |
13,864 |
1,319 |
| Green Eric Mark | President, CEO and Board Chair |
Feb 18 '25 |
Option Exercise |
211.00 |
2,461 |
519,269 |
170,369 |
| Witherspoon Charles | VP & Treasurer |
Oct 29 '24 |
Option Exercise |
173.22 |
478 |
82,799 |
1,956 |
| Witherspoon Charles | VP & Treasurer |
Oct 29 '24 |
Sale |
310.40 |
703 |
218,211 |
1,253 |
| Abraham Silji | SVP, Chief Technology Officer |
Oct 29 '24 |
Option Exercise |
0.00 |
458 |
0 |
3,318 |
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):